Working... Menu
Trial record 14 of 45 for:    MDM2

Milademetan Tosylate and Low-Dose Cytarabine in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03634228
Recruitment Status : Recruiting
First Posted : August 16, 2018
Last Update Posted : July 15, 2019
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
This phase I/II trial studies the side effects and best dose of milademetan tosylate and to see how well it works with cytarabine in treating participants with acute myeloid leukemia that has come back (recurrent) or that does not respond to treatment (refractory). Milademetan tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving milademetan tosylate and low-dose cytarabine may work better in treating participants with recurrent or refractory acute myeloid leukemia.

Condition or disease Intervention/treatment Phase
Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia TP53 wt Allele Drug: Cytarabine Drug: Milademetan Tosylate Phase 1 Phase 2

Detailed Description:


I. To evaluate the safety and tolerability. (Phase 1) II. To determine the recommended phase II dose. (Phase I) III. To evaluate the efficacy (by International Working Group [IWG] criteria - Phase 2) of the MDM2 inhibitor, milademetan tosylate (DS-3032b), in combination with low dose cytarabine (LDAC) in relapsed/refractory (non-TP53 mutant) patient population.


I. Evaluation of time to response variables including overall survival (OS), event-free survival (EFS) and duration of response (DOR).

II. Determine biomarkers that may be predictive of DS-3032b (milademetan tosylate) activity.

III. Molecular profiling at screening, on study, and at relapse to determine genomic predictors of response and resistance.

OUTLINE: This is a dose escalation study of milademetan tosylate, followed by a phase II study.

Participants receive low dose cytarabine subcutaneously (SC) twice daily (BID) on days 1-7 and receive milademetan tosylate orally (PO) once daily (QD) on days 8-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment participants are followed up at 30 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of the Oral MDM2 Inhibitor DS-3032b in Combination With Low Dose Cytarabine (LDAC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Actual Study Start Date : December 17, 2018
Estimated Primary Completion Date : May 1, 2020
Estimated Study Completion Date : May 1, 2021

Arm Intervention/treatment
Experimental: Treatment (low dose cytarabine, MDM2 inhibitor DS-3032b)
Participants receive low dose cytarabine SC BID on days 1-7 and receive milademetan tosylate PO QD on days 8-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Cytarabine
Given SC
Other Names:
  • .beta.-Cytosine arabinoside
  • 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
  • 1-.beta.-D-Arabinofuranosylcytosine
  • 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone
  • 1-Beta-D-arabinofuranosylcytosine
  • 1.beta.-D-Arabinofuranosylcytosine
  • 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-
  • 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-
  • Alexan
  • Ara-C
  • ARA-cell
  • Arabine
  • Arabinofuranosylcytosine
  • Arabinosylcytosine
  • Aracytidine
  • Aracytin
  • Aracytine
  • Beta-cytosine Arabinoside
  • CHX-3311
  • Cytarabinum
  • Cytarbel
  • Cytosar
  • Cytosine Arabinoside
  • Cytosine-.beta.-arabinoside
  • Cytosine-beta-arabinoside
  • Erpalfa
  • Starasid
  • Tarabine PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Drug: Milademetan Tosylate
Given PO
Other Names:
  • DS-3032 Tosylate
  • DS-3032b
  • DS-3032b Tosylate

Primary Outcome Measures :
  1. Incidence of adverse events (Phase I) [ Time Frame: Up to 1 year ]
    Graded according to Common Terminology Criteria for Adverse Events version 5.0.

  2. Maximum tolerated dose (MTD) (Phase I) [ Time Frame: Up to 28 days ]
    As determined by dose limiting toxicity (DLT). MTD is defined the highest dose at which no more than one patient out of 6 patients experience DLTs in the first cycle. A 3+3 algorithm will be applied for dose escalation or dose de-escalation.

  3. Overall response rate (Phase II) [ Time Frame: Up to 28 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have refractory or relapsed AML (salvage 1, 2, and 3)
  • TP53 wild-type status on molecular testing performed within the last 3 months
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Creatinine clearance >= 60 mL/min, as calculated using the modified Cockcroft-Gault equation OR creatinine =< 1.5 x upper limit of normal (ULN)
  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
  • Bilirubin =< 1.5 x ULN, unless resulting from hemolysis, Gilbert's disease or considered to be due to leukemic involvement
  • No gastrointestinal issues to interfere with oral medication absorption
  • No active uncontrolled infection or comorbidity that would interfere with therapy or place patient at increased risk
  • Subject (male and female) of childbearing/reproductive potential must agree to use double-barrier contraceptive measures or avoid intercourse during the study and for 90 days after the last dose of study drug
  • Subject must sign and date an Institutional Review Board-approved informed consent form (including Health Insurance Portability and Accountability Act authorization, if applicable) before performance of any study-specific procedures or tests
  • Able and willing to provide bone marrow biopsies/aspirates as requested by the protocol
  • Willing to undergo malignancy genotyping for TP53 mutation, insertion, or deletion at screening
  • A life expectancy of at least 3 months

Exclusion Criteria:

  • Patient with t(15;17) karyotypic abnormality or a diagnosis of acute promyelocytic leukemia
  • Patient with other malignancy that contains a non-synonymous mutation, insertion, or deletion in the TP53 gene determined previously or at screening
  • Prior treatment with an MDM2 inhibitor
  • Presence of central nervous system involvement of leukemia. History of prior leptomeningeal leukemia/disease that has fully resolved is eligible
  • A second concurrent primary malignancy that has required active treatment within the previous 2 years, except for localized cancers that have apparently been cured, for example non-melanoma skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast
  • Any condition that would preclude adequate absorption of DS-3032b, including refractory vomiting, malabsorption, biliary shunt, significant bowel resection, and/or graft-versus-host disease (GVHD) affecting the gut
  • Any active uncontrolled infection, known human immunodeficiency virus infection, or active hepatitis B or C infection
  • Any concomitant medical condition that would in the opinion of the investigator increase the risk of toxicity
  • Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5, grade =< 1 or baseline. Subjects with chronic grade 2 toxicities may be eligible per discretion of the investigator and sponsor (e.g., grade 2 chemotherapy-induced neuropathy)
  • Patient having received hematopoietic stem cell transplantation (HSCT) within 60 days of the first dose of DS-3032b, is on immuno-suppressive therapy post-HSCT at the time of screening, or has clinically significant GVHD (use of topical steroids for ongoing skin GVHD will be permitted)
  • Patient receiving treatment with a strong inhibitor or inducer of CYP3A4; patient receiving drugs that are strong CYP3A inhibitors within 7 days prior to the first dose and during treatment; patient receiving drugs that are strong inducers of CYP3A within 14 days prior to the first dose and during treatment
  • Received any therapies intended to treat malignancy within 14 days of first receipt of DS-3032b (except for hydroxyurea, which is allowed for control prior to and during the first cycle of study treatment
  • Prolongation of corrected QT interval by Fridericia's method (QTcF) at rest, where the mean QTcF interval is >= 450 ms for males or >= 470 ms for females based on triplicate electrocardiograms (ECGs). Patients with incomplete right bundle branch block (RBBB) and QTc above threshold will be eligible after principal investigator (PI) review
  • Pregnant or breastfeeding
  • Substance abuse or medical, psychological, or social conditions that, in the opinion of the investigator, may interfere with the subject's participation in the clinical study or evaluation of the clinical study results

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03634228

Layout table for location contacts
Contact: Kiran Naqvi 713-745-6877

Layout table for location information
United States, Texas
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Kiran Naqvi    713-745-6877      
Principal Investigator: Kiran Naqvi         
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Kiran Naqvi M.D. Anderson Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center Identifier: NCT03634228     History of Changes
Other Study ID Numbers: 2018-0333
NCI-2018-01612 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2018-0333 ( Other Identifier: M D Anderson Cancer Center )
P30CA016672 ( U.S. NIH Grant/Contract )
First Posted: August 16, 2018    Key Record Dates
Last Update Posted: July 15, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs